Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14349613 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2CA1CA2ALDH1A1KDM4E | |
| SCHEMBL1547465 | 0.85 | ALDH1A1 (0.41) | GAACA1CA2MMP1MMP2 | |
| SCHEMBL10913172 | 0.82 | GAA (0.53) | GAASMN1; SMN2CA1CA2MMP1 | |
| SCHEMBL5565548 | 0.81 | MEN1 (0.49) | SMN1; SMN2CA1CA2ALDH1A1HPGD | |
| SCHEMBL21971206 | 0.74 | GAA (0.52) | GAASMN1; SMN2CA1CA2MMP1 | |
| SCHEMBL28755044 | 0.74 | KEAP1 (0.44) | GAASMN1; SMN2CA1CA2MMP1 | |
| SCHEMBL6554634 | 0.72 | GAA (0.59) | GAASMN1; SMN2CA1CA2MMP1 | |
| SCHEMBL14349166 | 0.72 | EGFR (0.42) | SMN1; SMN2CA2ALDH1A1KDM4EHPGD | |
| SCHEMBL28611285 | 0.69 | GAA (0.55) | GAASMN1; SMN2CA1CA2MMP1 | |
| SCHEMBL3350774 | 0.69 | TDP1 (0.36) | GAASMN1; SMN2CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11981687-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4361128-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3880681-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4286387-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-4163284-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4148044-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230045079-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230039161-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-02-09 | — | — | US | disclosed |
| US-9873708-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050986-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050985-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2017015495-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015502-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015496-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20110207784-A1 | OXADIAZOLE-2-OXIDES AS ANTISCHISTOSOMAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2011-08-25 | — | — | US | disclosed |
| EP-2310378-A2 | OXADIAZOLE-2-OXIDES AS ANTISCHISTOSOMAL AGENTS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010019772-A2 | OXADIAZOLE-2-OXIDES AS ANTISCHISTOSOMAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981687-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | GAA 4380/4885SMN1; SMN2 2230/4885CA1 1376/4885 |
| US-11981688-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRA6 | GAA 4380/4885SMN1; SMN2 2230/4885CA1 1376/4885 |
| US-20230045079-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | GAA 4380/4885SMN1; SMN2 2230/4885CA1 1376/4885 |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | GAA 3909/4885SMN1; SMN2 1938/4885CA1 1079/4885 |
| US-20170050986-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | GAA 3909/4885SMN1; SMN2 1938/4885CA1 1079/4885 |
| US-20170050985-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | GAA 3909/4885SMN1; SMN2 1938/4885CA1 1079/4885 |
| US-20170051011-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | GAA 3909/4885SMN1; SMN2 1938/4885CA1 1079/4885 |
| US-20230039161-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRA6 | GAA 4380/4885SMN1; SMN2 2230/4885CA1 1376/4885 |
| US-20110207784-A1 | OXADIAZOLE-2-OXIDES AS ANTISCHISTOSOMAL AGENTS | ARG2, OXA1L, SQOR | GAA 604/4885SMN1; SMN2 1169/4885CA1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.